{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:13:38Z","timestamp":1787699618748,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["23A1002"],"award-info":[{"award-number":["23A1002"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.dld.2025.01.037","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T18:53:27Z","timestamp":1737226407000},"page":"877-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"57","author":[{"given":"Tsukasa","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-6814","authenticated-orcid":false,"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-8828","authenticated-orcid":false,"given":"Shinya","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1255-5201","authenticated-orcid":false,"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-0952","authenticated-orcid":false,"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Koshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.01.037_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.dld.2025.01.037_bib0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.01.037_bib0003","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.037_bib0004","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","article-title":"Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.01.037_bib0005","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.01.037_bib0006","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.dld.2025.01.037_bib0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12328-022-01593-w","article-title":"Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature","volume":"15","author":"Hori","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.037_bib0008","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2024.03.028","article-title":"Benefits of NSAIDs plus pancreatic stenting to prevent post-ERCP pancreatitis","volume":"167","author":"Hanscom","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.01.037_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.dld.2025.01.037_bib0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2025.01.037_bib0011","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.037_bib0012","first-page":"1222","article-title":"Electronic address: clinical Practice Guideline Panel: chair; Panel members; EASL Governing Board representative. EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.01.037_bib0013","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.01.037_bib0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.01.037_bib0015","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.01.037_bib0016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/hepr.14078","article-title":"Diagnostic guide for immune checkpoint inhibitor-induced liver injury","volume":"54","author":"Ito","year":"2024","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2025.01.037_bib0017","series-title":"Plymouth meeting: national comprehensive cancer network","article-title":"NCCN Guidelines Version 1.2024 management of immunotherapy-related toxicities","author":"Thompson","year":"2023"},{"key":"10.1016\/j.dld.2025.01.037_bib0018","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.01.037_bib0019","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.01.037_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.01.037_bib0021","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200663","article-title":"Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-fluorodeoxyglucose positron emission tomography","volume":"94","author":"Anderson","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.dld.2025.01.037_bib0022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2025.01.037_bib0023","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.01.037_bib0024","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jhep.2020.10.035","article-title":"IL-17A\/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression","volume":"74","author":"Stein","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.01.037_bib0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.15340","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort","volume":"43","author":"Berry","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.01.037_bib0026","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jjco\/hyaa201","article-title":"Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts","volume":"51","author":"Takinami","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.dld.2025.01.037_bib0027","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2025.01.037_bib0028","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.17898","article-title":"An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury","volume":"59","author":"Riveiro-Barciela","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.01.037_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2025.01.037_bib0030","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/hepr.14043","article-title":"Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team","volume":"54","author":"Ito","year":"2024","journal-title":"Hepatol Res"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:27:24Z","timestamp":1762554444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1590865825000386"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.01.037","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}